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Staphylococcus aureus bacteremia is a substantial cause 
of childhood disease and death, but few studies have de-
scribed its epidemiology in developing countries. Using a 
population-based surveillance system for pneumonia, sep-
sis, and meningitis, we estimated S. aureus bacteremia inci-
dence and the case-fatality ratio in children <5 years of age 
in 2 regions in the eastern part of The Gambia during 2008–
2015. Among 33,060 children with suspected pneumonia, 
sepsis, or meningitis, we performed blood culture for 27,851; 
of 1,130 patients with bacteremia, 198 (17.5%) were positive 
for S. aureus. S. aureus bacteremia incidence was 78 (95% 
CI 67–91) cases/100,000 person-years in children <5 years 
of age and 2,080 (95% CI 1,621–2,627) cases/100,000 per-
son-years in neonates. Incidence did not change after intro-
duction of the pneumococcal conjugate vaccine. The case-
fatality ratio was 14.1% (95% CI 9.6%–19.8%). Interventions 
are needed to reduce the S. aureus bacteremia burden in 
The Gambia, particularly among neonates.
In 2016, invasive bacterial diseases accounted for one quarter of the 5.6 million childhood deaths worldwide 
(1). Most invasive bacterial diseases occur in sub-Saharan 
Africa and other low- and middle-income countries (2). 
Deaths caused by these diseases outnumber those caused 
by malaria among children <5 years of age (3). The main 
bacteria implicated in invasive bacterial diseases has been 
Streptococcus pneumoniae and Haemophilus influenzae (4). 
However, after the widespread use of conjugate vaccines 
against H. influenzae type b (Hib) and S. pneumoniae, Hib 
disease has decreased considerably (5), and vaccine-sero-
type pneumococcal disease is declining (6). The decreased 
disease incidence associated with these pathogens has led 
to Staphylococcus aureus becoming a relatively more com-
mon cause of invasive bacterial disease (7). The clinical 
spectrum of S. aureus disease ranges from life-threatening 
invasive diseases, such as septicemia, pneumonia, osteo-
myelitis, endocarditis, meningitis, and brain abscess, to less 
severe skin and soft tissue infections. S. aureus bacteremia 
is often used as a marker of invasive S. aureus disease (8).
In high-income countries, S. aureus bacteremia is the 
second most common cause of neonatal sepsis, after group 
B Streptococcus (9). From the 1970s through the 2000s, 
the incidence of S. aureus bacteremia among children <16 
years of age increased in several countries (10), probably 
because of the increased use of central venous catheters and 
other factors (10). In the 2010s, the incidence of S. aureus 
bacteremia remained stable (11) or decreased (10).
In Africa, S. aureus bacteremia is a common cause 
of invasive bacterial disease in children. Before the intro-
duction of the Hib vaccine and pneumococcal conjugate 
vaccine (PCV), population-based studies in Kenya and 
Mozambique showed that S. aureus was the most com-
mon gram-positive pathogen among neonates with sepsis 
(4,12). Also, hospital-based studies showed S. aureus to 
be the most common cause of invasive bacterial disease in 
children <3 months of age in The Gambia (13) and one of 
the main causes of invasive bacterial disease in children <5 
years of age in Nigeria (14).
Few population-based studies have been conducted in 
sub-Saharan Africa on the incidence of S. aureus bactere-
mia. In South Africa, a population-based study of children 
<13 years of age in an area with a high HIV prevalence 
Staphylococcus aureus Bacteremia 
in Children of Rural Areas of  
The Gambia, 2008–2015
Aderonke Odutola, Christian Bottomley, Syed A. Zaman, Jodi Lindsay, Muhammed Shah,  
Ilias Hossain, Malick Ndiaye, Chidebere D.I. Osuorah, Yekini Olatunji, Henry Badji,  
Usman N.A. Ikumapayi, Ahmad Manjang, Rasheed Salaudeen, Lamin Ceesay, Momodou Jasseh, 
Richard A. Adegbola, Tumani Corrah, Philip C. Hill, Brian M. Greenwood, Grant A. Mackenzie
Author affiliations: London School of Hygiene and Tropical  
Medicine, London, UK (A. Odutola, C. Bottomley, S.A. Zaman, 
B.M. Greenwood, G.A. Mackenzie); Medical Research Council 
Unit The Gambia at the London School of Hygiene and Tropical 
Medicine, Banjul, The Gambia (A. Odutola, S.A. Zaman, M. Shah, 
I. Hossain, M. Ndiaye, C.D.I. Osuorah, Y. Olatunji, H. Badji,  
U.N.A. Ikumapayi, A. Manjang, R. Salaudeen, M. Jasseh,  
R.A. Adegbola, T. Corrah, G.A. Mackenzie); St. George’s  
University of London, London (J. Lindsay); King Fahad Medical 
City, Riyadh, Saudi Arabia (A. Manjang); Ministry of Health and 
Social Welfare, Banjul (L. Ceesay); University of Otago, Dunedin, 
New Zealand (P.C. Hill); Murdoch Children’s Research Institute, 
Parkville, Victoria, Australia (G.A. Mackenzie)
DOI: https://doi.org/10.3201/eid2504.180935
RESEARCH
702 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 25, No. 4, April 2019
indicated an incidence of 26 cases/100,000 person-years 
(15). A study in Kenya involving children admitted to a 
secondary healthcare facility showed an incidence of 27 
cases/100,000 person-years in children <5 years of age; the 
highest incidence was in infants (89 cases/100,000 person-
years) (4). However, variation in the age groups studied 
and methods used preclude direct comparison of these 
studies (4,12,13,15). After introduction of the Hib vaccine 
and before the introduction of PCV, a hospital-based study 
in The Gambia reported that S. aureus was the most com-
mon cause of bacteremia (16).
Given the paucity of population-based data on the epi-
demiology of S. aureus bacteremia in sub-Saharan Africa, 
we studied the incidence, clinical characteristics, case-
fatality rate, and risk factors for S. aureus bacteremia in 
young children in a rural region of The Gambia. We also 
explored the association of S. aureus bacteremia with the 
introduction of PCV.
Methods
Study Site and Population
Surveillance for septicemia, pneumonia, and meningitis 
was performed among children ≥2 months of age residing 
in Basse in the Upper River Region of The Gambia through 
the Basse Health and Demographic Surveillance System 
(BHDSS) (Figure 1).  We established the BHDSS in 2007, 
and the population in this surveillance area (≈179,000 per-
sons in 2015, 19% <5 years of age) is enumerated every 4 
months. The BHDSS is served by 5 satellite clinics and the 
Basse Health Centre (Basse, The Gambia), a primary and 
secondary healthcare facility with 25 beds to care for chil-
dren. During 2011–2015, surveillance was extended to in-
clude all residents <5 years of age, and a similar surveillance 
was set up in the adjacent district of Fuladu West for all 
residents <5 years of age during a similar time range (2012–
2014) through the Fuladu West Health and Demographic 
Surveillance System (FWHDSS; Figure 1). The population 
in Fuladu West is enumerated annually (population 92,464 
in 2014, 18% <5 years of age). The FWHDSS is served by 
Bansang Hospital (Bansang, The Gambia) and 2 satellite 
clinics. Every resident in the areas surveilled by the BHDSS 
and FWHDSS was assigned a unique identifier.
The conjugate vaccine for Hib was introduced into the 
Gambian National Programme on Immunization in 1997, 
and the vaccine for pneumococcus was introduced in 2009. 
The 7-valent PCV (PCV7) was replaced by the 13-valent 
vaccine (PCV13) in 2011. In 2012, vaccine coverage for 
the third dose of the diphtheria-pertussis-tetanus vaccine in 
these regions surveilled was 81.7% (17). In The Gambia, 
transmission of Plasmodium falciparum is largely restrict-
ed to the short rainy season during July–November (18).
Surveillance Procedures
During May 12, 2008–December 31, 2015, nurses screened 
all children 2–59 months of age who arrived at a health center 
participating in the surveillance and who had a unique identi-
fier for septicemia, pneumonia, and meningitis, according to 
standardized criteria (also referred to as referral surveillance) 
(19). Children who were admitted and children who were 
treated as outpatients were screened. Children who screened 
positive were referred to clinicians who used standardized 
criteria for assessment and investigation (19). Data collected 
included age, sex, anthropometric measurements, signs and 
symptoms, and suspected diagnosis. Blood was collected 
for culturing, and depending on clinical presentation, cere-
brospinal fluid, lung aspirate, or pleural fluid samples were 
have also been collected for conventional microbiological 
Figure 1. Regions surveilled for Staphylococcus aureus bacteremia among children <5 years of age through the Basse and Fuladu 
West Health and Demographic Surveillance Systems, The Gambia, 2008–2015. Inset indicates location of The Gambia in Africa.
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tests (6). Rapid diagnostic tests for malaria (ICT Malaria P.f. 
Antigen; ICT Diagnostics, http://www.ictdiagnostics.co.za) 
were routinely performed during the rainy season and at 
other times at the discretion of the clinician.
During March 1, 2011–December 31, 2015, surveil-
lance was expanded in the BHDSS to include all children 
0–59 months of age who were admitted with an acute medi-
cal problem from whom a blood sample was collected for 
culture (also referred to as admission surveillance). During 
September 12, 2011–December 31, 2014, a similar admis-
sion surveillance was conducted for children 0–59 months 
of age admitted with an acute medical problem using the 
FWHDSS. All S. aureus bacteremia cases were linked to 
the Health and Demographic Surveillance System databas-
es by using the unique identifier.
Laboratory Methods
We collected 1–3-mL blood samples from all patients with 
suspected septicemia, pneumonia, or meningitis; inoculat-
ed blood samples into BACTEC bottles (Becton Dickinson, 
https://www.bd.com); and incubated them in an automated 
BACTEC 9050 Blood Culture System (Becton Dickinson) 
for a maximum of 5 days. We subcultured positive cultures 
on blood agar plates and confirmed isolates as S. aureus by 
using catalase and coagulase tests. We classified cultures 
that grew Bacillus spp., Corynebacterium spp., and coag-
ulase-negative Staphylococcus as contaminated. We used 
standard methods to investigate other body fluid samples 
collected for microbiological tests (20). We used disc dif-
fusion methods to determine antimicrobial drug suscepti-
bility according to the Clinical and Laboratory Standards 
Institute guidelines (21). We categorized all S. aureus iso-
lates resistant to cefoxitin as methicillin-resistant.
We defined S. aureus bacteremia cases as clinically 
suspected cases of septicemia, pneumonia, meningitis, os-
teomyelitis, septic arthritis, pyomyositis, or abscess iden-
tified by using standardized criteria (19) in patients from 
whom S. aureus was isolated from their blood.
Statistical Methods
We used referral and admission surveillance data for sta-
tistical analyses. The unique identifier assigned to every 
patient enabled us to avoid duplication of data in our data 
set. We used the referral surveillance data to investigate 
trends in incidence because these data covered a longer 
period (2008–2015) than the admissions surveillance data 
(2011–2015). We used both the admission and referral sur-
veillance data to estimate age-specific incidence and the 
case-fatality ratio (CFR).
We obtained incidence estimates by dividing the number 
of S. aureus bacteremia cases by the number of person-years 
at risk using the estimated midyear population. To account 
for the shorter period of observation in 2008 (May 12– 
December 31), we calculated person-years at risk as the midyear 
population multiplied by 234/365. We calculated incidence in 
neonates using 2 methods, first as cases per 1,000 live births 
and second as cases per 100,000 person-years. We defined the 
neonatal period as the time from birth to 28 days of age.
With the referral surveillance data, we assessed trends 
in incidence over time and variation in incidence before 
(pre-PCV period, May 12, 2008–May 11, 2010) and after 
(PCV13 period, January 1, 2013–December 31, 2015) the 
introduction of PCV7 using Poisson regression with robust 
error variance to allow for overdispersion. To account for 
the increased rate of eligible patients requiring blood culture 
over time, we adjusted the number of S. aureus bacteremia 
cases of each age group and year by multiplying by the 
ratio of the annual rate of eligible children enrolled over 
the mean rate of eligible children enrolled during the entire 
study period (6). For the denominators of the pre-PCV and 
PCV13 periods, we used the average of the corresponding 
midyear populations indicated by the BHDSS.
We defined CFR as the number of patients with S. au-
reus bacteremia who died before discharge divided by the 
total number of patients with S. aureus bacteremia. We 
identified potential risk factors for death before discharge 
using logistic regression, although surveillance was not de-
signed to assess risk factors. We generated weight-for-age 
and weight-for-height z-scores using the 2006 World Health 
Organization child growth standards (https://www.who.int/
childgrowth/standards/technical_report). We considered 
children with weight-for-age z-scores <3 SDs from the me-
dian weight-for-age as severely underweight and weight-for-
height z-scores <3 SDs from the median weight-for-height 
as severely stunted. We performed analyses using Stata 14.0 
(https://www.stata.com/stata14) and considered p values 
<0.05 as the criterion for statistical significance.
Ethics Statement
Ethics approval for this study was granted by The Gambia 
Government/Medical Research Council Joint Ethics Com-
mittee and the London School of Hygiene and Tropical 
Medicine Ethics Committee. We obtained written informed 
consent from the parents or guardians of all patients.
Results
In total, 33,060 children met the criteria for investigation, 
and 27,851 (84.2%) blood samples were collected and 
cultured (Figure 2). Contaminants grew in the cultures of 
2,539 (9.1%) blood samples; these samples were excluded 
from analysis because contamination can mask an S. au-
reus bacteremia diagnosis.
Bacteremia
Bacteremia was identified in 1,130 children 0–59 months 
of age (Table 1). S. aureus was isolated in 198 (17.5%) 
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children with bacteremia (76 identified through referral 
surveillance and 122 admission surveillance) and was the 
most common cause of bacteremia in neonates (46.4%, 
84/181). Pathogens other than S. aureus were isolated from 
932 children: S. pneumoniae (35.0%, n = 326), Salmonella 
spp. (15.1%, n = 141), and Escherichia spp. (10.7%, n = 
100). In 7 children with bacteremia, S. aureus and a second 
bacterial pathogen were isolated.
Patient Characteristics
Using the combined admission and referral surveillance data, 
we found that 18.2% (4,541/24,885) of all patients were se-
verely underweight and 10.9% (2,658/24,405) were severely 
stunted; 18.3% (4,183/22,902) of patients were admitted in 
the 2 weeks before disease onset. Antimicrobial drug use in 
the week before onset of signs and symptoms was uncommon. 
Most patients had fever (≥37.5°C) and tachypnea (Table 1).
Among patients with S. aureus bacteremia, a diagno-
sis of suspected septicemia was made in 56.2%, suspected 
pneumonia in 28.4%, and suspected meningitis in 6.7%. 
The median duration of hospital stay was 5 (interquartile 
range 2–6) days (Table 1).
Cough and difficult breathing were experienced more 
often by patients without bacteremia or with bacteremia 
caused by other pathogens than by patients with S. aureus 
bacteremia (Table 1). S. aureus bacteremia patients were 
more likely to have a diagnosis of suspected septicemia or 
other focal sepsis and less likely to have a diagnosis of sus-
pected pneumonia than patients without bacteremia or with 
bacteremia caused by other pathogens (Table 1).
Incidence and Risk Factors for S. aureus Bacteremia
Using the combined referral and admission surveillance 
data (2011–2015 in BDHSS and 2012–2014 in FWDHSS), 
we found the incidence of S. aureus bacteremia to be 78 
(95% CI 67–91) cases/100,000 person-years in children 
0–59 months of age. The incidence was highest among 
neonates (2,080 [95% CI 1,621–2,627] cases/100,000 
person-years, 3.5 [95% CI 2.9–4.7] cases/1,000 live births) 
and decreased in older age groups (Table 2). Incidence of 
S. aureus bacteremia in the 1–11-month age group was 133 
(95% CI 99–174) cases/100,000 person-years, and inci-
dence in the 1–4-year age group was 27 (95% CI 20–36) 
cases/100,000 person-years. Among the 84 S. aureus bac-
teremia cases in neonates, 13 (15.5%) presented in the first 
week of life and 35 (41.7%) in the second. The incidence 
of S. aureus bacteremia was higher in the wet season than 
in the dry season (Table 2).
Trends in Incidence of S. aureus Bacteremia
Using referral surveillance data (2008–2015 in BDHSS), 
we found the mean annual incidence of S. aureus bacte-
remia in children 2–59 months of age to be 22.3 (95% CI 
16.7–29.2) cases/100,000 person-years. The incidence did 
not change over this period (p value for trend = 0.28), al-
though PCV vaccination coverage increased during this 
period (Figure 3).
Using the referral surveillance data, we observed that 
9 cases (10 cases after enrollment rate adjustment) of S. 
aureus bacteremia occurred in the pre-PCV period and 26 
cases (23 cases after enrollment rate adjustment) in the 
PCV13 period. The crude S. aureus bacteremia incidence 
was 16 cases/100,000 person-years in the pre-PCV period 
and 26 cases/100,000 person-years in the PCV13 period 
(incidence rate ratio 1.6, 95% CI 0.8–3.5; p = 0.19). With 
the increasing size of the population and after adjusting 
for increased enrollment of eligible children over time, 
no significant increase in S. aureus bacteremia incidence 
Figure 2. Flowchart of 
participants included 
and excluded in study of 
Staphylococcus aureus 
bacteremia incidence in children 
<5 years of age, The Gambia, 
2008–2015. Participants were 
identified through the Basse 
and Fuladu West Health and 
Demographic Surveillance 
Systems. In total, 521 cases 
were identified through referral 
surveillance and 418 through 
admission surveillance. 
*Reasons for not having 
blood culture done included 
unsuccessful venipuncture (n 
= 487), declined consent for 
venipuncture (n = 416), declined 
consent to join study (n = 249), and unknown (n = 4,057). †In total, 76 children were identified through referral surveillance and 122 
through admission surveillance. ‡Seven patients had polymicrobial bacteremia (S. aureus and a second bacterial pathogen).
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was found between the pre-PCV (18 cases/100,000 person-
years) and the PCV13 (23 cases/100,000 person-years) pe-
riods (incidence rate ratio 1.3, 95% CI 0.6–2.7; p = 0.49).
CFRs and Risk Factors Associated with Fatality
In total, 28 deaths occurred among 198 S. aureus bactere-
mia patients before discharge (CFR 14.1%, 95% CI 9.4%–
20.4%) (Table 1). In comparison, the CFR among patients 
without bacteremia was 3.6% (95% CI 3.3%–3.8%) and 
among patients with bacteremia with other pathogens 17.2% 
(95% CI 14.7%–20.1%). The S. aureus bacteremia CFR did 
not vary by year (p value for trend = 0.75) or age group (p 
value for trend = 0.99). Deaths associated with S. aureus bac-
teremia most often occurred on the day of admission (71.4%, 
20/28). During 2011–2015, S. aureus bacteremia deaths 
accounted for 7.0% (12/171) of all deaths in neonates and 
3.6% (24/662) of all deaths in children <5 years of age. The 
risk factors associated with death from S. aureus bacteremia 
 
Table 1. Characteristics of patients <5 years of age with suspected pneumonia, septicemia, or meningitis with or without 
Staphylococcus aureus bacteremia identified through 2 surveillance systems, The Gambia, 2008–2015* 
Patient characteristic 
Patients with S. aureus 
bacteremia, n = 198 
Patients with bacteremia caused 
by other pathogen, n = 932 
Patients without 
bacteremia, n = 24,182 
Age, mo    
 <1 84/198 (42.4) 97/932 (10.4) 1,911/24,177 (7.9) 
 1–11 61/198 (30.8) 310/932 (33.3) 8,675/24,177 (35.9) 
 12–23 33/198 (16.7) 265/932 (28.4) 7,505/24,177 (31.0) 
 24–59 20/198 (10.1) 260/932 (27.9) 6,086/24,177 (25.2) 
Sex    
 M 97/198 (49.0) 532/932 (57.1) 13,740/24,177 (56.8) 
 F 101/198 (51.0) 400/932 (42.9) 10,437/24,177 (43.2) 
Severely stunted† 20/109 (18.3) 216/884 (24.4) 3,425/21,736 (15.8) 
Mid-upper arm circumference <11 cm 81/198 (40.9) 184/932 (19.7) 3,080/24,182 (12.7) 
Admitted in previous 2 weeks 31/162 (19.1) 157/843 (18.6) 3,995/21,897 (18.2) 
Hospital stay, d, median (IQR) 5 (2–6) 4 (3–6) 3 (2–4) 
Disease onset during wet season‡ 97/198 (49.0) 335/932 (35.9) 10,335/24,171 (42.8) 
Died 28/198 (14.1) 161/932 (17.3) 860/24,182 (3.6) 
Symptoms    
 Cough 103/198 (52.0) 675/928 (72.7) 19,523/24,148 (80.8) 
 Difficult breathing 89/197 (45.2) 535/927 (57.7) 14,280/24,102 (59.2) 
 Prostration 29/197 (14.7) 147/918 (16.0) 1,602/23,906 (6.7) 
 Diarrhea 38/190 (20.0) 271/861 (31.5) 5,798/22,772 (25.5) 
 Convulsion 8/198 (4.0) 72/927 (7.8) 1,174/24,127 (4.9) 
Signs    
 Lower chest wall in-drawing 164/198 (82.8) 732/927 (79.0) 17,856/24,129 (74.0) 
 Meningism 1/192 (0.5) 34/867 (3.9) 174/22,841 (0.8) 
 Altered level of consciousness 124/193 (64.2) 407/873 (46.6) 9,590/23,518 (40.8) 
Axillary temperature    
 <36.5°C 18/198 (9.1) 79/932 (8.5) 2,405/24,182 (9.9) 
 36.5°C–37.5°C 40/198 (20.2) 147/932 (15.8) 6,819/24,182 (28.2) 
 >37.5°C 140/198 (70.7) 706/932 (75.7) 14,958/24,182 (61.9) 
Pulse rate, beats/min§    
 Increased for age 84/198 (42.4) 621/932 (66.6) 15,107/24,182 (62.5) 
Respiratory rate, breaths/min¶    
 Increased for age 128/198 (64.6) 682/932 (73.2) 17,157/24,177 (71.0) 
Oxygen saturation <92% 33/198 (16.7) 116/932 (12.4) 2,140/24,182 (8.8) 
Suspected diagnosis#    
 Septicemia 109/194 (56.2) 434/896 (48.4) 8,549/23,068 (37.1) 
 Pneumonia 55/194 (28.4) 347/896 (38.8) 13,244/23,068 (57.4) 
 Meningitis 13/194 (6.7) 96/896 (10.7) 718/23,068 (3.1) 
 Other focal sepsis 17/194 (8.8) 19/896 (2.1) 557/23,068 (2.4) 
Malaria positivity** 14/131 (10.7) 84/723 (11.6) 3,276/21,626 (15.1) 
*Values are no. patients/total no. in category (%) except as indicated. Surveillance data are from the Basse Health and Demographic Surveillance System 
and the Fuladu West Health and Demographic Surveillance System. IQR, interquartile range.  
†Defined as weight-for-height z-score <3 SDs from median weight-for-height for the corresponding age group. We calculated weight-for-height using z-
scores from the 2006 World Health Organization child growth standards in Stata 14.0 (https://www.stata.com/stata14). Neonates were not included in 
weight-for-height measurements. 
‡The wet season occurs during July–November and the dry season during December–June. 
§The reference ranges for pulse rates were 70–190 beats/min for children <1 month of age, 80–160 beats/min for children 1–11 months of age, 80–130 
beats/min for children 1–2 years of age, 80–120 beats/min for children 3–4 years of age, 75–115 beats/min for children 5–6 years of age, 70–110 
beats/min for children 7–9 years of age, and 60–100 beats/min for children >10 years of age. 
¶Increased respiratory rate was defined as >60 breaths/min for children <2 months of age, >50 breaths/min for children 2–12 months of age, >40 breaths/ 
min for children >1–5 years of age. 
#Surveillance diagnosis was categorized into mutually exclusive groups in order of severity; meningitis was considered more severe than septicemia, 
which was considered more severe than pneumonia. 
**Malaria was tested using a rapid diagnostic test (ICT Malaria P.f. Antigen, ICT Diagnostics, http://www.ictdiagnostics.co.za). 
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were prostration at clinical presentation and musculoskeletal 
swelling with or without tenderness (Table 3).
Treatment and Susceptibility of Isolates
Among S. aureus bacteremia patients identified through 
referral surveillance, 17.1% (13/76) received initial em-
piric therapy with cloxacillin, 23.7% (18/76) ampicillin, 
31.6% (24/76) penicillin, and 50.0% (38/76) gentamicin; 
50 (65.8%) of these patients received >1 antimicrobial 
drug. The mortality rate did not differ by empiric therapy. 
Among the 193 S. aureus isolates tested, 3.1% were meth-
icillin-resistant (Table 4).
Discussion
We estimated the incidence and CFR of S. aureus bac-
teremia in a rural part of The Gambia using surveillance 
data over a 5-year period and evaluated trends in incidence 
over an 8-year period. The incidence was high, particularly 
among neonates (3.5 cases/1,000 live births), but did not 
increase with time (Figure 3). The CFR (14.1%) was sub-
stantial (Table 1).
The observed incidence of S. aureus bacteremia in 
The Gambia among children 0–59 months of age (78.4 
cases/100,000 person-years) was higher than that for in-
dustrialized countries (6.5–42.0 cases/100,000 person-
years) (22,23) and some countries of Africa (4) and Asia 
(24,25), although lower than that reported for Mozam-
bique (12). S. aureus bacteremia incidence was reported 
to be 27 cases/100,000 person-years in children <5 years 
in Kenya (4) and 101 cases/100,000 person-years in Mo-
zambique (12). In Thailand, a study that reviewed nation-
al hospital-based data on bacteremia reported a S. aureus 
bacteremia incidence of 2.5 cases/100,000 person-years 
(24), whereas a population-based study in Bangladesh 
that focused on children 1–59 months of age with respira-
tory symptoms reported an incidence of 9.9 cases/100,000 
person-years (25). The differences in incidence among 
studies are likely related to the different selection crite-
ria used in the various studies, nutritional status of the 
patients, presence of concurrent medical conditions, or 
high levels of antimicrobial drug use without a prescrip-
tion, especially in Asia (26).
During 2008–2015, we found no trend in S. aureus 
bacteremia incidence in The Gambia. Researchers in in-
dustrialized countries have shown an increase in the pro-
portion of all bacteremia cases caused by S. aureus after the 
introduction of PCV (27). However, our data do not sup-
port an association between S. aureus bacteremia incidence 
and the introduction of PCV. Further studies in different 
settings could help confirm this finding.
The incidence of S. aureus bacteremia was highest 
in neonates, 8 times that reported in Kenya (4), and S. 
aureus was the most common cause of bacteremia in 
this age group. This finding is similar to those of other 
studies conducted in Africa (12,14), where S. aureus was 
responsible for 39.0%–56.2% of isolates recovered from 
neonates. S. aureus carriage, which is likely a prerequisite 
for disease, is also highest during the neonatal period, 
higher than the carriage of S. pneumoniae and H. influenzae 
(28). In addition to high rates of acquisition of S. aureus 
 
Table 2. Factors associated with Staphylococcus aureus bacteremia in children <5 years of age identified through 2 surveillance 
systems, The Gambia, 2011–2015* 
Variable 
No. cases/no. person-years 
at risk 
Incidence, cases/100,000 
person-years Incidence rate ratio (95% CI) p value 
Age, mo     
 24–59 18/128,994 14.0 1  
 12–23 29/44,433 65.3 4.70 (2.6–8.4)  
 1–11 53/39,969 132.6 9.50 (5.6–16.2)  
 <1 70/3,367 2079.0 148.99 (88.8–250.1) <0.001 
Sex     
 M 82/107,515 76.3 1  
 F 88/109,248 80.6 1.06 (0.8–1.4) 0.72 
Season     
 Dry 85/144,508 58.8 1  
 Wet 85/72,255 117.6 2.00 (1.5–2.7) <0.001 
*Surveillance data are from the Basse Health and Demographic Surveillance System and the Fuladu West Health and Demographic Surveillance System 
 
Figure 3. Unadjusted annual incidence of Staphylococcus aureus 
bacteremia (cases/100,000 person-years) in children 2–59 months 
of age, Basse, The Gambia, 2008–2015. Cases were identified by 
referral surveillance through the Basse Health and Demographic 
Surveillance System. Arrows indicate introduction of PCV7 
and PCV13. PCV7, 7-valent pneumococcal conjugate vaccine; 
PCV13, 13-valent pneumococcal conjugate vaccine.
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during the neonatal period, other reasons for the high risk 
for S. aureus bacteremia might include an immature im-
mune system (29).
In our study, only 16% of the S. aureus bacteremia cas-
es in neonates presented within the first week of life, unlike 
for group B Streptococcus disease, where 80% of parents 
seek treatment for their neonates within this period (30). 
Reasons for the difference in timing of treatment might re-
late to the age at and source of S. aureus acquisition.
We found S. aureus bacteremia to be more common 
during the wet season. This seasonal variation might 
relate to S. aureus colonization (a prerequisite for dis-
ease), which is highest during the wet season (31), or 
seasonal differences in the incidence of viral infections, 
which are known to disrupt mucosal epithelium, thereby 
encouraging S. aureus invasion (32). In a study of US 
adults (33), the peak incidence of S. aureus infection oc-
curred during the winter months and coincided with the 
peak incidence of viral infections. In Africa, the inci-
dence of viral infections usually peaks during the wet 
season (34), coinciding with the peak S. aureus bactere-
mia incidence.
 
Table 3. Sociodemographic and clinical parameters associated with death from Staphylococcus aureus bacteremia among children <5 
years of age identified through 2 surveillance systems, The Gambia, 2008–2015* 
Parameter Deaths/persons at risk (%) Unadjusted OR (95% CI) p value Adjusted OR (95% CI)† p value 
Age, mo      
 <1 13/84 (15.5) Referent  Referent  
 1–11 8/61 (13.1) 0.8 (0.3–2.1)  0.9 (0.4–2.6)  
 12-23 4/33 (12.1) 0.8 (0.2–2.5)  1.3 (0.4–4.6)  
 24-59 3/20 (15.0) 1.0 (0.3–3.8) 0.96‡ 1.1 (0.3–4.6) 0.96 
Sex      
 M 16/97 (16.5) Referent    
 F 12/101 (11.9) 0.7 (0.3–1.5) 0.35   
Severely stunted§      
 No 20/150 (13.3) Referent    
 Yes 5/41 (12.2) 0.9 (0.3–2.6) 0.85   
Axillary temperature      
 36.5°C–37.5°C 4/18 (22.2) Referent    
 <36.5°C 4/40 (10.0) 0.4 (0.1–1.8)    
 >37.5°C 20/140 (14.3) 0.6 (0.2–2.0) 0.48   
Pulse rate, beats/min¶      
 Within reference ranges 13/114 (11.4) Referent    
 Increased for age 15/84 (17.9) 1.7 (0.8–3.8) 0.20   
Respiratory rate, breaths/min#      
 Within reference ranges 8/70 (11.4) Referent    
 Increased for age 20/128 (15.6) 1.4 (0.6–3.5) 0.41   
Need for oxygen supplementation      
 No 21/165 (12.7) Referent    
 Yes 7/33 (21.2) 1.9 (0.7–4.8) 0.22   
Season      
 Dry 18/101 (17.8) Referent    
 Wet 10/97 (10.3) 0.5 (0.2–1.2) 0.13   
Cough      
 No 13/95 (13.7) Referent    
 Yes 15/103 (14.6) 1.1 (0.5–2.4) 0.86   
Difficult breathing      
 No 14/108 (13.0) Referent    
 Yes 14/89 (15.7) 1.3 (0.6–2.8) 0.58   
Prostration      
 No 17/168 (10.1) Referent  Referent  
 Yes 11/29 (37.9) 5.4 (2.2–13.4) 0.0004 5.7 (2.2–14.8) 0.01 
Admitted in previous 2 weeks      
 No 20/131 (15.3) Referent    
 Yes 2/31 (6.5) 0.4 (0.1–1.7) 0.16   
*Surveillance data are from the Basse Health and Demographic Surveillance System and the Fuladu West Health and Demographic Surveillance System. 
OR, odds ratio.  
†Adjusted for age only. 
‡p value for trend. 
§Defined as weight-for-height z-score <3 SDs from median weight-for-height for the corresponding age group. We calculated weight-for-height using z-
scores from the 2006 World Health Organization child growth standards in Stata 14.0 (https://www.stata.com/stata14). Neonates were not included in 
weight-for-height measurements. 
¶The reference ranges for pulse rates were 70–190 beats/min for children <1 month of age, 80–160 beats/min for children 1–11 months of age, 80–130 
beats/min for children 1–2 years of age, 80–120 beats/min for children 3–4 years of age, 75–115 beats/min for children 5–6 years of age, 70–110 
beats/min for children 7–9 years of age, and 60–100 beats/min for children >10 years of age. 
#Increased respiratory rate was defined as >60 breaths/min for children <2 months of age, >50 breaths/min for children 2–12 months of age, >40 breaths/ 
min for children >1–5 years of age. 
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The CFR in our study was similar to (10) or greater 
than that reported by others (12,23). Variation in CFRs 
could be explained by differences between study popula-
tions in terms of age, quality of and access to healthcare, 
focus of infection, antimicrobial drug resistance rates, se-
verity of S. aureus bacteremia, or presence of concurrent 
medical conditions. In our study, 71.4% of deaths occurred 
on the day of admission, which might be a reflection of 
severity of disease when care was sought. Even though age 
is strongly associated with S. aureus bacteremia–related 
death (10,11), in our study CFR did not vary with age.
The strengths of our study were that the surveillance was 
population-based and uninterrupted and that blood culture 
was performed on >84% of eligible patients. However, the 
study also had some limitations. First, incidence might have 
been underestimated because some persons with S. aureus 
bacteremia never seek treatment at hospitals and the sensi-
tivity of blood culture is <100%. Second, an increasing rate 
of enrollment and investigation over time required adjust-
ment of annual case counts. Third, prior use of antimicrobial 
drugs, although uncommon in our study area, might have re-
duced the detection of S. aureus bacteremia by blood culture. 
Last, our study was not specifically designed to evaluate risk 
factors for S. aureus bacteremia. For example, S. aureus na-
sal carriage, hospitalization in the previous 6 months, and 
HIV status were not systematically assessed.
In conclusion, we demonstrated that the incidence of 
S. aureus bacteremia is high in rural Gambia, especially in 
neonates and infants. Strategies are urgently needed to re-
duce the burden of S. aureus bacteremia and should target 
children in their first month of life.
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